《双特异性T细胞衔接器治疗急性淋巴细胞白血病中国专家共识(2024年版)》解读

Interpretation of Chinese consensus for the bispecific T cell engager in the treatment of acute lymphoblastic leukemia(2024)

文章主要对《中华血液学杂志》发表的《双特异性T细胞衔接器治疗急性淋巴细胞白血病中国专家共识(2024年版)》进行解读。作为B细胞急性淋巴细胞白血病(B-cell acute lymphoblastic leukemia,B-ALL)领域目前唯一上市的双特异性T细胞衔接器分子,贝林妥欧单抗在多个临床研究中被证明能为B-ALL患者带来良好的生存获益和可管理的安全性。本解读深入分析贝林妥欧单抗的关键临床研究数据,立足当下,展望未来,探讨了B-ALL领域治疗格局改变的方向。

To interpret the Chinese consensus for the bispecific T cell engager in the treatment of acute lymphoblastic leukemia(2024),which was published in the Chinese Journal of Hematology.As the first and only approved bispecific T cell engager molecule,blinatumomab has been proven to provide significant survival benefits and manageable safety profiles in numerous clinical trials.This interpretation focuses on analyzing key clinical trial data for blinatumomab,discussing current findings,and exploring future directions for the evolving treatment landscape in B-cell acute lymphoblastic leukemia.